EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis

Cancer Research

Volumn 67, Issue 20, 2007, Pages 9800-9808

  Huang, Xiaoyong ^a,b   Yamada, Yoshihiro ^b   Kidoya, Hiroyasu ^b   Naito, Hisamichi ^b   Nagahama, Yumi ^b   Kong, Lingyu ^b   Katoh, Shin Ya ^b   Li, Weng Lin ^a   Ueno, Masaya ^b   Takakura, Nobuyuki ^b  

^a KANAZAWA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR B4; MONOCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYONAL TISSUE; GENE OVEREXPRESSION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL GROWTH PROCESSES; EPHRIN-B2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, WISTAR; RECEPTOR, EPHB4; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 35449001573     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0531     Document Type: Article

References (40)

1. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
2. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and vein s revealed by ephrinB2 and its receptor EphB4. Cell 1998;93:741-53.
3. Adams RH, Wilkinson GA, Weiss C, et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999;13:295-306.
4. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999;4:403-14.
5. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signaling. Nat Rev Mol Cell Biol 2002;3:475-86.
6. Mellitzer G, Xu Q, Wilkinson DG. Control of cell behaviour by signalling through Eph receptors and ephrins. Curr Opin Neurobiol 2000;10:400-8.
7. Gale NW, Baluk P, Pan L, et al. Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. Dev Biol 2001;230:151-60.
8. Wilkinson DG. Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2001;2:155-64.
9. Knoll B, Drescher U. Ephrin-As as receptors in topographic projections. Trends Neurosci 2002;25:145-9.
10. Barrios A, Poole RJ, Durbin L, Brennan C, Holder N, Wilson SW. Eph/Ephrin signaling regulates the mesenchymal-to-epithelial transition of the paraxial mesoderm during somite morphogenesis. Curr Biol 2003;13:1571-82.
11. Adams RH. Vascular patterning by Eph receptor tyrosine kinases and ephrins. Semin Cell Dev Biol 2002;13:55-60.
12. Adams RH, Klein R. Eph receptors and ephrin ligands: essential mediators of vascular development. Trends Cardiovasc Med 2000;10:183-8.
13. Adams RH, Diella F, Hennig S, Helmbacher F, Deutsch U, Klein R. The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell 2001;104:57-69.
14. Nakamoto M, Bergemann AD. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 2002;59:58-67.
15. Batlle E, Bacani J, Begthel H, et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005;435:1126-30.
16. Liu W, Ahmad SA, Jung YD, et al. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 2002;94:934-9.
17. Xia G, Kumar SR, Masood R, et al. Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res 2005;11:4305-15.
18. Xia G, Kumar SR, Stein JP, et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 2006;25:769-80.
19. Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM. The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol 2006;102:15-21.
20. Berclaz G, Flutsch B, Altermatt HJ, et al. Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. Oncol Rep 2002;9:985-9.
21. Masood R, Kumar SR, Sinha UK, et al. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer 2006;119:1236-48.
22. Berclaz G, Karamitopoulou E, Mazzucchelli L, et al. Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol 2003;14:220-6.
23. Takai N, Miyazaki T, Fujisawa K, Nasu K, Miyakawa I. Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer. Oncol Rep 2001;8:567-73.
24. Tang XX, Brodeur GM, Campling BG, Ikegaki N. Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma. Clin Cancer Res 1999;5:455-60.
25. Sorokin L, Girg W, Gopfert T, Hallmann R, Deutzmann R. Expression of novel 400-kDa laminin chains by mouse and bovine endothelial cells. Eur J Biochem 1994;223:603-10.
26. Zhang XQ, Takakura N, Oike Y, et al. Stromal cells expressing ephrin-B2 promote the growth and sprouting of ephrin-B2(+) endothelial cells. Blood 2001;98:1028-37.
27. Takakura N, Yoshida H, Ogura Y, Kataoka H, Nishikawa S, Nishikawa S. PDGFRα expression during mouse embryogenesis: immunolocalization analyzed by whole-mount immunohistostaining using the monoclonal anti-mouse PDGFRα antibody APA5. J Histochem Cytochem 1997;45:883-93.
28. Takakura N, Watanabe T, Suenobu S, et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000;102:199-209.
29. Takakura N, Huang XL, Naruse T, et al. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity 1998;9:677-86.
30. Okamoto R, Ueno M, Yamada Y, et al. Hematopoietic cells regulate the angiogenic switch during tumorigenesis. Blood 2005;105:2757-63.
31. Holmberg J, Clarke DL, Frisen J. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 2000;408:203-6.
32. Cowan CA, Henkemeyer M. Ephrins in reverse, park and drive. Trends Cell Biol 2002;12:339-46.
33. Depaepe V, Suarez-Gonzalez N, Dufour A, et al. Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature 2005;435:1244-50.
34. Kertesz N, Krasnoperov V, Reddy R, et al. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 2006;107:2 330-8.
35. Martiny-Baron G, Korff T, Schaffner F, et al. Inhibition of tumor growth and angiogenes is by soluble EphB4. Neoplasia 2004;6:248-57.
36. Erber R, Eichelsbacher U, Powajbo V, et al. EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J 2006;25:628-41.
37. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A 2004;101:5583-8.
38. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
39. Bennett BD, Wang Z, Kuang WJ, et al. Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily. J Biol Chem 1994;269:14211-8.
40. Vogt T, Stolz W, Welsh J, et al. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increasedt umorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res 1998;4:791-7.